Rommel, Anna-Sophie
James, Sarah-Naomi
McLoughlin, Gráinne
Brandeis, Daniel
Banaschewski, Tobias
Asherson, Philip
Kuntsi, Jonna
Funding for this research was provided by:
Action Medical Research (GN2080, GN1777)
National Institute of Mental Health (R01MH062873)
Medical Research Council (G0300189, MR/J500380/1)
Article History
Received: 10 December 2016
Accepted: 26 May 2017
First Online: 2 June 2017
Compliance with ethical standards
:
: The Study of Preterm birth and Inattention (SPIN) and the Sibling EEG Follow-up Study (SEFOS) were supported by generous grants from Action Medical Research and the Peter Sowerby Charitable Foundation to Prof. Kuntsi (GN2080 (SPIN) and GN1777 (SEFOS)). Initial sample recruitment of the SEFOS ADHD sample was supported by NIMH Grant R01MH062873 to Prof. Faraone; the recruitment of the SEFOS control sample and initial cognitive assessments of ADHD and control groups were supported by UK Medical Research Council Grant G0300189 to Prof. Kuntsi. Dr. Rommel was supported by a 1 + 3 Medical Research Council studentship (MR/J500380/1).
: Prof. Brandeis has served as an unpaid scientific advisor for an EU-funded Neurofeedback trial. Prof. Banaschewski has served in an advisory or consultancy role for Actelion, Hexal Pharma, Eli Lilly and Co., Medice, Novartis, Oxford outcomes, PCM scientific, Shire, and Viforpharma. He has received conference support or speaker’s fee by Medice, Novartis, and Shire. He is/has been involved in clinical trials conducted by Shire and Viforpharma. He has received royalties from Hogrefe, Kohlhammer, CIP Medien, and Oxford University Press. Prof. Asherson has received funding for research by Vifor Pharma, and has given sponsored talks and been an advisor for Shire, Janssen-Cilag, Eli Lilly and Co., Flynn Pharma, and Pfizer, regarding the diagnosis and treatment of ADHD. All funds are received by King’s College London and used for studies of ADHD. Drs. Rommel, James and McLoughlin and Prof. Kuntsi report no biomedical financial interests or potential conflicts of interest.